Cargando…

A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells

Conventionally, immunotoxins have been produced as a single polypeptide from fused genes of an antibody fragment and a toxin. In this study, we adopted a unique approach of chemical conjugation of a toxin protein and an antibody fragment. The two genes were separately expressed in Escherichia coli a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Sunju, Park, Sangsu, Nguyen, Minh Tan, Lee, Eunyoung, Kim, Julee, Baek, Sangki, Kim, Chong Jai, Jang, Yeon Jin, Choe, Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society for Biochemistry and Molecular Biology 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726212/ https://www.ncbi.nlm.nih.gov/pubmed/30670149 http://dx.doi.org/10.5483/BMBRep.2019.52.8.250

Ejemplares similares

Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered Pseudomonas exotoxin A
por: Lee, Byeong Sung, et al.
Publicado: (2019)

Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
por: Kim, Hyun Jung, et al.
Publicado: (2020)

HER2 c-Terminal Fragments Are Expressed via Internal Translation of the HER2 mRNA
por: Godfrey, Jack D., et al.
Publicado: (2022)

Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion
por: Park, Sangsu, et al.
Publicado: (2021)

Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens
por: Ahn, Sangjeong, et al.
Publicado: (2015)

A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis
por: Leung, Kin-Mei, et al.
Publicado: (2015)

HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution
por: Ding, Haozhong, et al.
Publicado: (2020)

In Vitro Evaluation of Vegf-Pseudomonas Exotoxin: A Conjugated on Tumor Cells
por: Langari, Jahangir, et al.
Publicado: (2017)

Evaluation of an (131)I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers
por: Feng, Yutian, et al.
Publicado: (2022)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Rapid Evaluation of Antibody Fragment Endocytosis for Antibody Fragment–Drug Conjugates
por: Kim, Eunhee G., et al.
Publicado: (2020)

High throughput cytotoxicity screening of anti-HER2 immunotoxins conjugated with antibody fragments from phage-displayed synthetic antibody libraries
por: Hou, Shin-Chen, et al.
Publicado: (2016)

Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1
por: Sochaj-Gregorczyk, Alicja M., et al.
Publicado: (2017)

Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy
por: Jeong, Hwa Yeon, et al.
Publicado: (2020)

HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
por: Seo, An Na, et al.
Publicado: (2014)

Identification of Relevant Conformational Epitopes on the HER2 Oncoprotein by Using Large Fragment Phage Display (LFPD)
por: Gabrielli, Federico, et al.
Publicado: (2013)

Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer
por: Chen, Feng, et al.
Publicado: (2018)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
por: Gandullo‐Sánchez, Lucía, et al.
Publicado: (2020)

Overexpression of HER2/HER3 and clinical feature of ovarian cancer
por: Chung, Ye Won, et al.
Publicado: (2019)

Drugs of Dependency: The Pregnant Woman and Her Infant
por: Oei, Julee, et al.
Publicado: (2011)

Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer
por: Xu, Chen, et al.
Publicado: (2017)

Preparation and evaluation of the exotoxin A nano-gold conjugate as a vaccine candidate for Pseudomonas aeruginosa infections
por: Abbasi, Masoumeh, et al.
Publicado: (2021)

Prokaryotic soluble overexpression and purification of oncostatin M using a fusion approach and genetically engineered E. coli strains
por: Nguyen, Minh Tan, et al.
Publicado: (2019)

HER2 signaling regulates HER2 localization and membrane retention
por: Jeong, Jaekwang, et al.
Publicado: (2017)

Development of an Anti-HER2 Single-Chain Variable Antibody Fragment Construct for High-Yield Soluble Expression in Escherichia coli and One-Step Chromatographic Purification
por: Byun, Kyu Tae, et al.
Publicado: (2023)

Pseudomonas Exotoxin A: optimized by evolution for effective killing
por: Michalska, Marta, et al.
Publicado: (2015)

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells
por: Serwotka-Suszczak, Anna M., et al.
Publicado: (2017)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Neuropeptide analogs, conjugates, and fragments
Publicado: (1993)

Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHER2 mice: characterization and use in a model of metastatic breast cancer
por: Park, Sunju, et al.
Publicado: (2017)

Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Demonstration of protein-fragment complementation assay using purified firefly luciferase fragments
por: Ohmuro-Matsuyama, Yuki, et al.
Publicado: (2013)

Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
por: Zhang, Hang, et al.
Publicado: (2017)

Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells
por: Damiani, Isabella, et al.
Publicado: (2021)

Novel Bacterial Production of Two Different Bioactive Forms of Human Stem-Cell Factor
por: Lee, Eunyoung, et al.
Publicado: (2021)

An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers
por: Shin, Seol Hwa, et al.
Publicado: (2021)

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
por: Weng, Weining, et al.
Publicado: (2023)

Serial Serum HER2 Measurements for the Detection of Breast Cancer Recurrence in HER2-Positive Patients
por: Ha, June-Hyung, et al.
Publicado: (2014)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7np8rttvp48rssquqb2oul15ni